Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
Cogent Biosciences (Nasdaq: COGT) has announced its upcoming participation in a fireside chat at the Leerink Healthcare Conference scheduled for March 12, 2025, at 10:00 a.m. ET. The event will be accessible via webcast on the company's Investors & Media webpage, with replay available for 30 days.
Additionally, the company disclosed an inducement equity grant approved by its Compensation Committee on March 4, 2025. Under Nasdaq Listing Rule 5635(c)(4), a new employee received options to purchase 90,000 shares of Cogent common stock. The option features a 10-year term, with a 4-year vesting schedule: 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Cogent Biosciences (Nasdaq: COGT) ha annunciato la sua prossima partecipazione a un incontro informale durante la Leerink Healthcare Conference, programmato per il 12 marzo 2025, alle 10:00 ET. L'evento sarà accessibile tramite webcast sulla pagina web Investitori & Media della società, con la registrazione disponibile per 30 giorni.
Inoltre, la società ha rivelato un'indennità azionaria approvata dal suo Comitato per la Compensazione il 4 marzo 2025. Ai sensi della Regola di Quotazione Nasdaq 5635(c)(4), un nuovo dipendente ha ricevuto opzioni per acquistare 90.000 azioni di azioni ordinarie Cogent. L'opzione prevede un termine di 10 anni, con un piano di vesting di 4 anni: il 25% si acquisisce dopo un anno e il restante si acquisisce mensilmente per 36 mesi, soggetto a continua occupazione.
Cogent Biosciences (Nasdaq: COGT) ha anunciado su próxima participación en una charla informal en la Leerink Healthcare Conference programada para el 12 de marzo de 2025, a las 10:00 a.m. ET. El evento será accesible a través de un webcast en la página web de Inversores y Medios de la compañía, con una repetición disponible durante 30 días.
Además, la empresa divulgó una concesión de acciones como incentivo aprobada por su Comité de Compensación el 4 de marzo de 2025. Según la Regla de Cotización Nasdaq 5635(c)(4), un nuevo empleado recibió opciones para comprar 90,000 acciones de acciones ordinarias de Cogent. La opción tiene un plazo de 10 años, con un calendario de adquisición de 4 años: el 25% se adquiere después de un año y el resto se adquiere mensualmente durante 36 meses, condicionado a la continuación del empleo.
코겐트 바이오사이언스(Cogent Biosciences) (Nasdaq: COGT)는 2025년 3월 12일 오전 10시(동부 표준시)에 예정된 리어링크 헬스케어 컨퍼런스에서의 파이어사이드 챗에 참여할 것이라고 발표했습니다. 이 행사는 회사의 투자자 및 미디어 웹페이지를 통해 웹캐스트로 접근할 수 있으며, 30일 동안 다시 볼 수 있습니다.
또한, 회사는 2025년 3월 4일 보상위원회에서 승인한 유인 주식 보조금을 공개했습니다. 나스닥 상장 규칙 5635(c)(4)에 따라, 새로운 직원은 코겐트의 보통주 90,000주를 구매할 수 있는 옵션을 받았습니다. 이 옵션은 10년의 기간을 가지며, 4년의 베스팅 일정이 있습니다: 1년 후 25%가 베스팅되고, 나머지는 36개월 동안 매월 베스팅됩니다. 이는 계속 고용되는 조건에 따릅니다.
Cogent Biosciences (Nasdaq: COGT) a annoncé sa prochaine participation à une discussion informelle lors de la Leerink Healthcare Conference prévue pour le 12 mars 2025 à 10h00 ET. L'événement sera accessible via un webcast sur la page Investisseurs & Médias de l'entreprise, avec une rediffusion disponible pendant 30 jours.
De plus, la société a révélé une attribution d'actions incitatives approuvée par son Comité de Rémunération le 4 mars 2025. Conformément à la Règle de Cotation Nasdaq 5635(c)(4), un nouvel employé a reçu des options pour acheter 90 000 actions d'actions ordinaires Cogent. L'option a une durée de 10 ans, avec un calendrier d'acquisition de 4 ans : 25 % s'acquièrent après un an et le reste s'acquiert mensuellement sur 36 mois, sous réserve d'une poursuite de l'emploi.
Cogent Biosciences (Nasdaq: COGT) hat seine bevorstehende Teilnahme an einem Fireside-Chat auf der Leerink Healthcare Conference angekündigt, die für den 12. März 2025 um 10:00 Uhr ET geplant ist. Die Veranstaltung wird über einen Webcast auf der Investoren- und Medien-Webseite des Unternehmens zugänglich sein, mit einer Wiederholung, die 30 Tage lang verfügbar ist.
Darüber hinaus gab das Unternehmen eine Genehmigung für eine Anreizaktienzuteilung bekannt, die am 4. März 2025 von seinem Vergütungsausschuss genehmigt wurde. Gemäß der Nasdaq-Listing-Regel 5635(c)(4) erhielt ein neuer Mitarbeiter Optionen zum Kauf von 90.000 Aktien von Cogent-Stammaktien. Die Option hat eine Laufzeit von 10 Jahren mit einem 4-jährigen Vesting-Plan: 25% vesten nach einem Jahr, der Rest vestet monatlich über 36 Monate, abhängig von einer fortgesetzten Anstellung.
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Leerink Healthcare Conference on Wednesday, March 12, 2025 at 10:00 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grant of an “inducement” equity award on March 4, 2025 to one new employee under the company’s 2020 Inducement Plan. The award was approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employee received a nonqualified option to purchase 90,000 shares of Cogent common stock. The option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
What is the vesting schedule for COGT's new employee stock options granted in March 2025?
How many shares were included in Cogent Biosciences' March 2025 inducement grant?
When is Cogent Biosciences presenting at the Leerink Healthcare Conference 2025?
How long will the replay of COGT's Leerink Conference presentation be available?
